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Trials need participants but not their
feedback? A scoping review of published
papers on the measurement of participant
experience of taking part in clinical trials
Claire Planner1,2*, Peter Bower1,2 , Ailsa Donnelly1, K. Gillies3, Katrina Turner4 and Bridget Young2,5
Abstract
Background: Participant recruitment and retention are long-standing problems in clinical trials. Although there are
a large number of factors impacting on recruitment and retention, some of the problems may reflect the fact that
trial design and delivery is not sufficiently ‘patient-centred’ (i.e., sensitive to patient needs and preferences). Most
trials collect process and outcome measures, but it is unclear whether patient experience of trial participation itself
is routinely measured. We conducted a structured scoping review of studies reporting standardised assessment of
patient experience of participation in a trial.
Methods: A structured search of Medline, PsycINFO, Embase and CINAHL (Cumulative Index to Nursing and Allied
Health Literature) and hand searching of included studies were conducted in 2016. Additional sources included
policy documents, relevant websites and experts. We extracted data on trial context (type, date and location) and
measure type (number of items and mode of administration), patient experience domains measured, and the
results reported. We conducted a narrative synthesis.
Results: We identified 22 journal articles reporting on 21 different structured measures of participant experience in
trials. None of the studies used a formal definition of patient experience. Overall, patients reported relatively high
levels of global satisfaction with the trial process as well as positive outcomes (such as the likelihood of future
participation or recommendation of the trial to others).
Conclusions: Current published evidence is sparse. Standardised assessment of patient experience of trial
participation may provide opportunities for researchers to enhance trial design and delivery. This could
complement other methods of enhancing the patient-centredness of trials and might improve recruitment,
retention, and long-term patient engagement with trials.
Keywords: Trial, Participation, Patient experience, Patient satisfaction, Patient-centred trials
Background
Randomised controlled trials (RCTs) are often described
as the ‘gold standard’ method for assessment of effective-
ness because they offer the most rigorous way of deter-
mining cause–effect relationships [1]. Yet, despite the
efforts expended to deliver trials, recruitment and reten-
tion still pose significant challenges. A review of 73 pub-
lically funded multi-centre trials in the UK—delivered
through the National Institute for Health Research
(NIHR) Health Technology Assessment and Medical Re-
search Council programmes—found that only 55% re-
cruited 100% of their target sample size within their pre-
agreed timescale but that nearly 45% received an exten-
sion of some kind [2]. There is little evidence of major
improvement over time [3].
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Success in recruitment and retention is often consid-
ered to reflect trial design and management. However,
trials are dependent on the willingness of patients to give
their time and effort and to agree to randomisation and
follow-up. One potential way of increasing the willing-
ness of patients to participate is to design and conduct
trials that are aligned with the ‘wants, needs and prefer-
ences’ of patients (i.e., applying the concept of patient-
centred care to trials) [4].
Patient and public involvement (PPI) in research is the
process of involving patients and the public in shaping
the design of research and has the aim of making re-
search responsive to the needs of potential research par-
ticipants [5, 6]. There is growing evidence concerning
the optimal ways to achieve effective involvement of pa-
tients in research design and emerging evidence that
such work is having demonstrable benefits [7–10]. How-
ever, the focus of PPI is on patient and public input to
trial design and delivery. There is far less focus on asses-
sing the output of such work in terms of the actual ex-
perience of participants in those trials where PPI has
been implemented. Comprehensive and routine meas-
urement of patient experience in trials could provide im-
portant evidence on the effects of endeavours to make
trials ‘patient-centred’.
The concept of participant experience
There is no formal definition of patient experience in
the context of trials or research. A recent review identi-
fied four aspects common to many definitions of patient
experience, which are relevant for trials in the healthcare
setting: (1) the sum of all interactions (2) shaped by an
organisation’s culture (3) which influences patient per-
ceptions (4) across the continuum of care [11].
Different types of patient experience have been distin-
guished in the literature [12]. Preferences are ideas about
what should occur in interactions with research studies.
Reports are objective observations of those interactions
(e.g., the amount of time spent completing question-
naires as a measure of ‘research burden’). Evaluations
are reactions to the experience of doing research, in
terms of whether it was good or bad. For the purposes
of this article, we were interested in reports and evalua-
tions as measures of patient experience in trials as op-
posed to preferences about what should occur.
A number of different aspects of a trial may be im-
portant in terms of patient experience. These might in-
clude recruitment (information and consent),
randomisation (the need for such allocation and the way
it is explained and conducted), research treatment deliv-
ery, outcome measurement and follow-up, and ‘close
out’ (results sharing). Patient experience of these aspects
may impact on their overall satisfaction with participa-
tion and wider outcomes of participation (whether a
patient would participate again or would recommend
participation to friends and family).
What are the potential benefits of patient experience
measurement?
There is increasing consensus that measurement is a ne-
cessary aspect of quality improvement [13]. Tradition-
ally, the assessment of patient experience in routine
healthcare settings (outside the context of clinical trials)
has been secondary with a far greater focus on out-
comes. However, increasing patient involvement in
healthcare decision-making has led to renewed interest
in measurement of patient experience as a way of under-
standing the performance of healthcare systems and as a
driver of quality improvement [14]. For example, in the
UK, large-scale measurement of the experience of mil-
lions of primary care patients is conducted routinely and
is used as a barometer of system performance and an
impetus to quality improvement [15]. Although patient
experience may not be accorded the same weight as
health outcomes, it may be an important complement to
those traditional measures.
Although traditional outcome measures will always re-
main the focus of trials, we argue in this paper that rou-
tine measurement of patient experience in trials could
provide similar benefits to those found in routine health
care settings. There is much research that has explored
participants’ experience within trials but has involved
qualitative research focussed on certain aspects of the
trial (e.g., understanding of randomisation or informed
consent) and on a subset of patients or professionals [16,
17]. Though critical to improving trial delivery by ex-
ploring the perceptions of participants and developing
an understanding of the process [18], such work could
be usefully complemented by structured assessments of
the wider experience of the whole trial sample. Detailed
qualitative evaluation is resource-intensive and may not
be practical in routine trial contexts.
Most trials already undertake comprehensive measure-
ment on patients and so have a ready platform to assess
the experience of their participants. If assessment of ex-
perience were carried out on a routine basis, it might
allow measurement of variation over time, between
population subgroups within the trial, and could poten-
tially allow identification of problems and challenges
which may act as barriers to successful completion of
current or future trials. Effective feedback loops might
allow deployment of interventions to enhance partici-
pant experience and increase engagement with re-
search—a policy goal the UK NIHR has outlined in its
report Promoting a Research Active Nation [19].
However, at present, there is no agreed-upon standar-
dised methodology to capture patient experience in tri-
als, and it is unclear whether the routine measurement
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of patient experience is widespread. Our aim was to re-
view the literature to identify use of standardised mea-
sures of participant experience in a trial.
Our objectives were to do the following:
 Identify studies (involving any type of participant,
intervention, comparison or outcomes) using a
standardised measure of patient experience of trial
participation.
 Characterise the measures in terms of purpose,
format and aspects of participant experience that
were assessed.
 Report existing findings on patient experience within
the identified studies.
 Make recommendations for future development and
application of participant experience measurement.
Method
We conducted a ‘scoping review’, which allowed us to
‘map’ this research area and provide an initial overview
[20]. We reported the study according to the new guide-
lines for scoping reviews [21]. There was no review
protocol.
Searches
The search of databases was performed in June 2016 by
the lead author CP. Searches were limited to English lan-
guage articles and non-English articles with English ab-
stracts. The reference lists of included studies, grey
literature, policy documents and relevant websites were
also searched, and experts in the field of clinical trials
were contacted via the UK Clinical Research Collabor-
ation (UKCRC) Registered Clinical Trials Units Network
(https://www.ukcrc-ctu.org.uk/) to discuss published
work and ongoing studies in this area.
Information sources
We searched Medline, PsycINFO and CINAHL (Cumu-
lative Index to Nursing and Allied Health Literature)
from 1999 to 2016. The following search terms (text
words and medical subject headings) were used: Trial*
OR RCT OR treatment effectiveness evaluation AND
experience OR satisfaction or patient experience OR
participant experience OR attitude. We checked the ref-
erence lists of included studies for further references but
did not conduct citation searches on eligible studies.
There were no restrictions placed on type of trial, popu-
lation or condition. Search terms were reviewed and
tested for sensitivity with an information specialist. The
search prioritised sensitivity over specificity.
Study inclusion and exclusion criteria
We included studies using standardised measures which
could be either patient self-report or interviewer
administered. All titles and abstracts were screened by
CP, and the decision to include or exclude was recorded.
If multiple papers were published (e.g., reporting on dif-
ferent outcomes), the multiple reports were treated as a
single study but all publications were referenced. Studies
were managed by using Reference Manager software.
We excluded measures not related to health research
and measures which focus on only one aspect of a trial
(e.g., recruitment and informed consent).
Data charting and synthesis
Data were extracted from papers according to three
main categories:
 Trial context (type of trial, date run, and location of
sites) and population (age, gender and condition)
 Participant experience measure, which included the
measure name, type (report and evaluation),
administration (interviewer and self-report), and the
aspects of patient experience measured
 Summary of results reported
Data were extracted and recorded by CP only. We
undertook a narrative analysis of the results in line with
our research objectives.
Results
The search identified 2041 records, and 67 full text arti-
cles were retrieved. Fifty-seven were excluded for various
reasons (the most common being a conference abstract
only). Twelve additional articles were identified through
searching the reference lists of those studies. We identi-
fied a total of 22 journal articles reporting on 21 differ-
ent structured measures of participant experience in
trials (Fig. 1). The key features of the measures are de-
scribed below and summarised in Tables 1 and 2 [22–
43]. (Fuller details of the included studies are presented
in Additional file 1.)
Trial context
Of the measures identified, the majority assessed experi-
ence on single trials (n = 13). The majority (n = 12) were
published since 2000 and were conducted in the United
States (n = 7), United States and Canada (n = 2), or Eur-
ope (n = 7). The measures assessed participant experi-
ence in varied clinical contexts, including cancer care,
dentistry, arthritis and emergency medicine.
Types of measures within the trials
All of the measures focussed on evaluations (reactions
to the experience of doing research, in terms of whether
it was good or bad) rather than reports (objective obser-
vations of interactions; e.g., the amount of time spent
completing questionnaires).
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Defining participant experience and measure
development
None of the articles offered a formal definition of par-
ticipant experience, and only one reported a psychomet-
ric analysis which included validity and reliability testing.
Format, mode of delivery and time points
Where reported, the administration of the measure
was by self-report (n = 15) or interview (n = 4) or a
combination (n = 1) and measures were sent to partici-
pants by post (n = 10) or used in person (n = 3) or a
combination (n = 1).
Of the 16 articles that reported the number of items
included in the measure, the mean was 21 (range of 6–
76). None of the articles reported the completion time
for either self-report or interviewer administered mea-
sures. Of those that reported the administration time
point, the majority were administered at the end of the
trial (n = 14), one study measured 4 weeks after enrol-
ment, and only one study required participants to
complete a measure on more than one occasion.
Participants
Participant characteristics were reported in 19 of the ar-
ticles, and there was considerable variation in the range
of characteristics reported. Three articles reported the
percentage of people who withdrew from the trial but
completed the measure, which ranged from 3.9% to
8.6%.
Domains assessed
As summarised in Table 2, content of the measures var-
ied, but common aspects included global measures of
experience (such as satisfaction with overall experience),
measures of specific aspects of relevance to all trials
(such as informed consent), measures of aspects relevant
Fig. 1 Scoping study inclusion flowchart
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Table 1 Summary of articles reporting on participant experience measures
Study Geographical
location(s)
Number of
trials or
facilities in
the study
Delivery and
administration
Items Participants surveyed (response rate) Domains
Almeida et
al. (2007)
[22]
Portugal 1 facility Self-report
In person
Before discharge
from the study
14 136 (100%) i) Motivations for taking part
ii) Perception of informed
consent
iii) Perception of study
participation
Aman et al.
(1995) [23]
Not reported 2 trials Self-report
Postal
4 weeks after
enrolment
6 63 (63.5%) i) Staff characteristics
ii) Study operations
iii) Specific features of trial
iv) Incentives and
reinforcements
Bahati et al.
(2010) [24]
East Africa 3 facilities Interviewer
Not reported
Study end
Not
reported
Not reported (98%) i) Satisfaction with service
received
ii) Satisfaction with major
components of the research
study
Bertoli et
al. (2007)
[25]
Argentina 3 trials Self-report
Postal
Not reported
34 114 (94.6%) i) Socio-demographics
ii) Overall trial satisfaction
iii) Quality of information
given by the Investigator
iv) Participants’ self-
perception of knowledge
about randomised con-
trolled trials (RCTs)
v) Objective evaluation of
participants’ knowledge
about RCTs
Bevan et al.
(1993) [26]
UK 1 trial Interviewer
In person
Not reported
Not
reported
199 (99%) i) Reasons for participation
or declining participation
ii) Aspects of trials disliked
Cain et al.
(2005) [27]
UK and
Republic of
Ireland
Self-report
Postal
Study end
23 44 (82%) i) Information provided
ii) Reasons for taking part
iii) Best and worst aspects
of participation
iv) Willingness to participate
in the future
Dias et al.
(2005) [28]
Not reported 1 trial Self-report
Postal
3.5 year follow-up
19 469 (88%) i) Staff characteristics
ii) Study operations
iii) Specific features of trial
iv) Incentives and
reinforcements
Fearn et al.
(2010) [29]
UK 1 trial Self-report
Postal
Study end
Not
reported
910 (59%) i) Motivations for taking part
ii) Health professional
involvement
iii) Randomisation
iv) Filling in questionnaires
v) Experience of
participation
Friesen et
al. (2016)
[30]
USA 1 trial Self-report
In person
At final clinic
appointment
47 180 (98%) i) Attitudes towards trials
ii) Working with study team
iii) Perception of risk benefit
iv) General satisfaction
Van
Gelderen,
et al. (1993)
[31]
The
Netherlands
10 trials Self-report
Combination of
postal, taken
home and at end
of trial
Study end
12 153 (94%) i) Reason for participation
ii) Information received
iii) Most unpleasant aspects
iv) Most pleasant aspects
v) Experience of
participation
Hassar et
al. (1976)
[32]
USA 1 trial Interviewer
Not reported
Study end
12 1503 (80%) i) Reasons for investigators
taking part
ii) Participant impression of
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Table 1 Summary of articles reporting on participant experience measures (Continued)
Study Geographical
location(s)
Number of
trials or
facilities in
the study
Delivery and
administration
Items Participants surveyed (response rate) Domains
clinical studies
iii) Medical practice in
general
Henzlova et
al. (1994)
[33]
USA and
Canada
1 trial Self-report
Not reported
Before close out
visit
10 4751 (74%) i) Primary motivation for
participation
ii) Satisfaction with
participation and perceived
outcome
iii) Effect on health-
conscious behaviour
iv) Negative experiences
Kost et al.
(2013) [34,
35]
USA 29 facilities Self-report
Not reported
Study end
76 18,890 (29% of participants surveyed) i) Informed consent
ii) Trust
iii) Coordination of care
iv) Information, education
and communication
v) Respect for participant
preferences
Luzurier et
al. (2015)
[36]
France 1 trial Self-report
Not reported
Not reported
Not
reported
210 (% not reported) i) Satisfaction (with overall
welcome and protocol
management)
ii) Motivation for taking part
iii) Participation outlook
Martin et
al. (2011)
[37]
USA 3 trials Self-report
Postal
Not reported
47 75 (89%) i) Understanding of
participation
ii) Reasons for participating
iii) General experience
iv) Overall satisfaction
v) Willingness to participate
in a future study including a
placebo-controlled trial
McAdam et
al. (2002)
[38]
Not reported 1 trial Not reported
Not reported
Not reported
7 21 (81%) i) Information provided
ii) Staff
iii) Research processes
iv) Research outcomes
v) Willingness to participate
in the future
Mattson et
al. (1985)
[39]
USA 1 trial Self-report/
Interview
Postal
Before final
follow-up
5 1503 (80%) i) Perceived benefits
ii) Perceived beneficiaries
iii) Perceived disadvantages
iv) Perceived effects of
medication
v) Participation in a future
trial
Renfroe et
al. (2002)
[40]
USA and
Canada
1 trial Self-report
Postal
Study end
7 664 (71%) i) Would participate again
ii) Main reasons for
participation
iii) Study benefits
iv) Study problems
v) Quality of care.
Schron et
al. (1997)
[41]
USA 1 trial Self-report
Postal
Final follow-up
(4.5 years after
enrolment)
10 4281 (82%) i) Reason for participating
ii) Satisfaction with
participating
Tangrea et
al. (1992)
[42]
USA 1 trial Self-report
Postal
Study end
7 891 (97%) i) Benefits
ii) Most unpleasant aspects
iii) Importance
iv) Satisfaction
v) Physical well-being
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to trial interventions (such as treatment side effects), and
outcomes (such as willingness to participate again or the
likelihood of recommending a trial to family and friends).
Some studies included additional measures which were
not related to the specific experience of the trial but might
be important drivers of that experience (such as motiv-
ation for taking part and expectations around experience).
None of the studies asked participants for their feedback
on the participant experience measure itself.
Results of the patient experience measures
Given the variability in the trials and study populations,
comparison of the results must be made with caution.
Response rates to the patient experience measure varied
but were broadly in line with what might be expected
from the usual rates achieved in trial outcome measures.
Response rates ranged from 29% to 100%. Of those stud-
ies reporting response rates, 15 (75%) out of 20 reported
rates over 80%, which is usually seen as a marker of
quality [44].
Overall, participants reported high levels of global sat-
isfaction with the process. When asked, a majority of
participants suggested that they would participate in tri-
als in the future, and 11 (85%) out of 13 studies reported
that outcome. Nevertheless, some trials did report less
positive experience from a significant minority of partici-
pants. For example, one in five participants did not rate
information and informed consent highly in one study
[25], whereas in another study, nearly half felt that par-
ticipation interfered with their family routine [37]. In an-
other study, only 52% reported willingness to participate
in further research in another [29]. There were insuffi-
cient studies to permit any sensible assessment of factors
across studies related to participant experience.
Discussion
Summary of results
Our search of the literature found a relatively small
number of eligible studies. Measuring participant
experience does not appear to be common in the pub-
lished literature, making it difficult to quantify key as-
pects of experience, such as levels of satisfaction or
dissatisfaction with trial processes, or to explore patient
or trial characteristics associated with satisfaction. How-
ever, there may be a significant grey literature that our
search failed to uncover.
From the limited data presented, it would seem that
generally respondents express high levels of satisfaction
and are positive about further participation and recom-
mendations to others. Although this is an important
finding, there is a significant potential for publication
bias (as results critical of a trial may be less likely to be
published), and it is possible that patients who are likely
to take part in trials may have experienced higher-
quality care more generally. Even in the context of the
broadly positive results, some of the trials did report less
positive experience from a significant minority of
participants.
It is not clear how much focus should be placed on
the experience of patients participating in trials com-
pared with those preferences and experiences of people
who do not participate in trials. Obviously, in many trial
contexts, the latter far outnumber the former. Of course,
it is possible that the experience of patients in trials will
provide insights which can translate to better propor-
tions of patients being recruited in the first place. How-
ever, the drivers of participation and good experience
may be different.
Limitations of the studies
Studies had a number of limitations, including the lack
of a formal definition of patient experience and the use
of measures without detailed data about their develop-
ment or psychometric characteristics. However, these
limitations are to be expected in a developing research
area. Response rates to the patient experience measures
were generally acceptable, but clearly there is the poten-
tial for bias if patients with particular experiences are
Table 1 Summary of articles reporting on participant experience measures (Continued)
Study Geographical
location(s)
Number of
trials or
facilities in
the study
Delivery and
administration
Items Participants surveyed (response rate) Domains
vi) Willingness to take active
treatment if shown to be
effective
vii) Participation in future
trials
Verheggen
et al. (1998)
[43]
The
Netherlands
26 trials Personal
interview (at start
of the trial)
Telephone
interview (3
months later)
Not
reported
Personal interview = 172 (93%); Telephone
interview = 172 (78.5%); control group (only
participating in telephone interview) = 34
(100%)
i) Medical technical aspects
ii) Interpersonal
iii) Organisational aspects
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Table 2 Summary of domains measured (shaded boxes represent domains measured)
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less likely to return measures, along with participants
who withdraw or are eligible but decide not to partici-
pate. As with trials more generally, research could use-
fully explore ways to maximise return rates [45, 46].
Strengths and limitations of the review
We have characterised our study as a scoping review, as
we did not conduct a formal quality appraisal. The
search was designed to provide a reasonable balance be-
tween sensitivity and the resources available to the re-
view. Assessment of papers and data extraction
were conducted by a single reviewer. We do not feel that
these limitations are critical given our focus on scoping
the current evidence on the use of standardised ques-
tions and the very limited evidence reported. There is no
standardised system for quality assessment of the types
of studies included in the scoping review, which could
have been assessed as surveys (through criteria such as
response rates and data completeness) and as measure-
ment studies (in terms of psychometric criteria such as
reliability and validity). This would have required a po-
tentially complex assessment which may not have been
proportionate given the aims of the scoping review.
Our search for the scoping review was relatively cir-
cumscribed in order to keep the yield of the search man-
ageable. The search was conducted in mid-2016, and
resource limitations meant that we have been unable to
update the search. It is possible that new studies have
been published, although we would not expect major
changes in the evidence base or the conclusions of our
review. As with any search, the focus was on published
work and we may have missed unpublished work carried
out by trial teams or research units. There may be a
wider literature in the commercial sector, where there is
much current interest in concepts such as ‘patient-cen-
tricity’ as applied to trials. We did not contact industry
experts as part of our scoping work. Our discussions
with local trial teams do not suggest that measurement
of patient experience is widespread, although some re-
search contexts (such as dedicated research facilities)
may be better able to conduct this sort of work, and the
Clinical Research Network in the UK has begun system-
atic work on patient experience [47]. If there is ‘hidden
literature’ about what happens in trials (in internal re-
ports or in the tacit knowledge of investigators), it would
be important to understand how that could be better re-
ported and used.
The author team has tried to ensure a patient perspec-
tive on the issues raised in this paper. Workshops ex-
ploring the concept of a ‘patient-centred’ trial were run
alongside this scoping review (http://research.bmh.man-
chester.ac.uk/patientcentredtrials/resources/) and pa-
tients were involved in those workshops alongside a
range of professional stakeholders. Author AD is a
patient representative who has had a long-standing in-
volvement in this project, and our future funded work in
this area will include extensive PPI. Nevertheless, it is
important to be aware of the tension between the patient
perspective on trial participation and the interests of
professional stakeholders, which are often (though not
exclusively) focussed on recruitment and retention. We
expect that, in many cases, the goal of improving patient
experience will be aligned with the outcomes of im-
proved recruitment and retention, but it is important to
be aware that there may be cases in which there is ten-
sion between them (e.g., where retention may be en-
hanced by proactive follow-up, which some patients may
find burdensome).
Implications
From the literature identified by our review, it would ap-
pear that information about participant experience is not
systematically reported on individual studies, trial units,
centres or research facilities. As well as providing feed-
back for research staff on individual trials, standardised
assessment could be aggregated to allow assessment of
participant experience across multiple trials across a tri-
als unit or across a funder’s portfolio. This might allow
identification of broader trends which need higher-level
intervention.
Before adoption of standardised measurement of par-
ticipant experience, there are many issues that need con-
sideration. We outline some recommendations for
future research in this area, in terms of both the prac-
tical issues about how data are collected and wider issues
concerning the meaning and interpretation of the data.
Practical issues concerning the collection of patient
experience data
 What are the core dimensions of a ‘patient-centred’
trial that should be included in a participant
experience measure? Table 2 highlights variation in
what aspects of patient experience are measured in
different studies and suggests that global experience,
specific aspects of the trial (such as informed
consent) and positive and negative aspects of
participation are most likely to be measured. It is
not clear which aspects are most important to
patients or other stakeholders (such as trial teams
and funders) or how evaluations of the different
aspects are associated, as they may reflect a global
assessment. Effective priority-setting methods such
as those used in previous assessments of patient pri-
orities around trials may be useful in this regard
[48]. It will be important to identify the generic
questions of relevance to all trials and others that
may be important for particular trials or in
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particular contexts. A modular approach to meas-
urement (with generic and trial-specific measures)
may be optimal.
 What are the optimum format and delivery mode of
patient experience measures? Further work is
required to understand the optimum way in which
to collect experience data. All of the studies found
in our review measured evaluations rather than
reports, although it is unclear why that is the case.
Most studies evaluated experience at the end of the
study, which allows a more comprehensive
assessment of the entire experience of participation
but raises issues concerning the ability of
participants to recall earlier aspects of the trial.
 What is the correct balance between quantitative
and qualitative approaches to measuring patient
experience? Clearly, there is a significant qualitative
literature on patient experience in trials [16, 49] and
it will be important to explore the optimal methods
by which they can complement each other to take
advantage of their relative strengths.
 How can developments in technology facilitate
measurement? Developments in technology may
improve the collection of patient experience data in
the future. For example, digital recording of patient
narratives might be analysed by using text mining to
allow efficient capture of data that is richer than
standardised measures.
 Should measurement of patient experience be
independent of the trial team? Independence may
better avoid bias and the perception of pressure but
that may not be feasible in the context of limited
resources available to trial teams. The impact of
such independence on assessments could be
assessed by using the Study-Within-A-Trial design
[50].
Issues in the interpretation of patient experience data
 It is important to understand what influences
patient experience and how much of the variation in
experience is due to context and trial type, patient
characteristics, or aspects of the trial. There is an
ongoing debate as to whether adjusting for such
factors is a fairer way of assessing performance or
whether such adjustment removes the imperative to
improve care [51].
 In terms of factors related to the trial itself, it will be
important to determine how much of the variation
in patient experience is due to specific processes
(how patients are approached, how consent is
gained, and preferences considered) [52] compared
with the general interpersonal and communication
skills of staff [53]. Effective ‘closure’ in trials
(thanking patients for participation and providing
results) may be as important as their experience in
the trial itself [54].
 Another methodological issue of interest is
whether patients can distinguish between their
experience of the interventions within a trial and
their experience of the other trial procedures.
Acceptability of interventions will often be
assessed in pragmatic trials as part of a
comprehensive assessment of the value of the
intervention. Some aspects of patient experience
may be beyond the control of the trial team
(such as the result of their randomised allocation
and the outcomes patients achieve from
treatment).
 It will be important to explore the relative
importance placed on the measurement of patient
experience in different types of trials. For example,
some trials have little active patient participation or
even awareness of participation (such as cluster
trials without individual consent), where a focus on
patient experience may be less relevant.
 It will also be important to consider the costs
and other disadvantages of a focus on patient
experience in trials. There may be potential
unintended consequences of measures of patient
experience (such as causing trial teams to focus
on aspects of experience that are easily
measurable compared with more complex issues).
Work in this area will also have to be aware of
the wider literature on the concept of
‘satisfaction’ and its measurement [55–57].
Although measurement of participant experience
may be necessary for quality improvement, it is un-
likely to be sufficient. It will be important to assess
what other facilitators and resources need to be in
place to ensure that results lead to improvement and
that trial teams ensure a ‘virtuous circle’ between
measurement, feedback, and the design and delivery
of trials. We will be exploring how data can be used
for quality improvement in our ongoing funded
work, drawing on published examples of the use of
feedback in other contexts [58]. The wider literature
in audit and feedback would suggest that positive
impacts are most likely when baseline performance
is poor and when the feedback comes from a col-
league (which in this context might be other trialists
rather than others sharing a particular professional
background). Developing a ‘virtuous circle’ would re-
quire regular feedback, using multiple formats, with
clear targets and a plan for remedial action [59].
Adoption of appropriate theory may have an import-
ant role to play [60].
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Recommendations for describing participant experience
measurement
We identified some deficiencies in the reporting of the
use of patient experience measures in our scoping re-
view. We recommend reporting on the following:
 Whether the measure was used to assess experience
in one trial or across a trial portfolio.
 Trial context (trial phase, condition under
investigation, and core features of intervention)
 Location where the trial or trials were conducted
(country and facility where applicable)
 Development detail (e.g., how the items were
selected, estimated completion times, and whether
the measure has been subject to reliability and
validity testing)
 Number of participants invited to complete the
measure and response rate
 Percentage of participants who complete the
measure who withdrew from the trial (failure to
adhere to the protocol or provide routine follow-up
data)
 Participant characteristics, including demographics
(and other characteristics which may be relevant to
specific trial/facility)
 Delivery mode (postal, face-to-face interview, tele-
phone interview, and online) and administration
time points
 Any incentives or tokens of thanks given to
participants for completing the measure
 Number of items and response options (if the
measure is not published as part of the article)
 Details for how the measure can be sourced (and
languages available).
Conclusions
The regular and standardised assessment of participant
experience of trials could provide useful feedback for trial
teams, complement other methods of assessing patient ex-
perience, and assist in the development of patient-centred
trials. At present, there is little evidence that measurement
is conducted routinely. We outline key questions in this
area to promote research around this issue.
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